Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
(4) - EconoTimes)
BERKELEY, Calif., May 07, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on May 1, 2018 the Compensation Committee of Dynavax’s Board of Directors (the “Committee”) approved the grant of inducement stock options to purchase an aggregate of 79,000 shares of common stock to 10 new employees, and on May 3, 2018, the Committee approved the grant of inducement stock options to purchase an additional 10,000 shares of common stock to two new employees. These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $17.10 and $16.25 per share, the closing prices of Dynavax’s common stock on the respective effective dates of such grants, May 1, 2018 and May 3, 2018. The stock options awarded vest over a three-year period, with one-third of the shares subject to such awards vesting on the first anniversary of the award’s vesting commencement date, and 1/36th of the shares subject to such awards vesting monthly thereafter, subject to each such employee’s continued employment with Dynavax on such vesting dates.
Dynavax is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
David Burke
Director, Investor Relations & Corporate Communications
510.665.7269
[email protected]
